ABSTRACT
BACKGROUND: Herpes zoster, commonly known as shingles, is a neurocutaneous disease caused by the reactivation of the virus that causes varicella (chickenpox). After resolution of the varicella episode, the virus can remain latent in the sensitive dorsal ganglia of the spine. Years later, with declining immunity, the varicella zoster virus (VZV) can reactivate and cause herpes zoster, an extremely painful condition that can last many weeks or months and significantly compromise the quality of life of the affected person. The natural process of ageing is associated with a reduction in cellular immunity, and this predisposes older adults to herpes zoster. Vaccination with an attenuated form of the VZV activates specific T-cell production avoiding viral reactivation. Two types of herpes zoster vaccines are currently available. One of them is the single-dose live attenuated zoster vaccine (LZV), which contains the same live attenuated virus used in the chickenpox vaccine, but it has over 14-fold more plaque-forming units of the attenuated virus per dose. The other is the recombinant zoster vaccine (RZV) which does not contain the live attenuated virus, but rather a small fraction of the virus that cannot replicate but can boost immunogenicity. The recommended schedule for the RZV is two doses two months apart. This is an update of a Cochrane Review first published in 2010, and updated in 2012, 2016, and 2019. OBJECTIVES: To evaluate the effectiveness and safety of vaccination for preventing herpes zoster in older adults. SEARCH METHODS: For this 2022 update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL 2022, Issue 10), MEDLINE (1948 to October 2022), Embase (2010 to October 2022), CINAHL (1981 to October 2022), LILACS (1982 to October 2022), and three trial registries. SELECTION CRITERIA: We included studies involving healthy older adults (mean age 60 years or older). We included randomised controlled trials (RCTs) or quasi-RCTs comparing zoster vaccine (any dose and potency) versus any other type of intervention (e.g. varicella vaccine, antiviral medication), placebo, or no intervention (no vaccine). Outcomes were cumulative incidence of herpes zoster, adverse events (death, serious adverse events, systemic reactions, or local reaction occurring at any time after vaccination), and dropouts. DATA COLLECTION AND ANALYSIS: We used the standard methodological procedures expected by Cochrane. MAIN RESULTS: We included two new studies involving 1736 participants in this update. The review now includes a total of 26 studies involving 90,259 healthy older adults with a mean age of 63.7 years. Only three studies assessed the cumulative incidence of herpes zoster in groups that received vaccines versus placebo. Most studies were conducted in high-income countries in Europe and North America and included healthy Caucasians (understood to be white participants) aged 60 years or over with no immunosuppressive comorbidities. Two studies were conducted in Japan and one study was conducted in the Republic of Korea. Sixteen studies used LZV. Ten studies tested an RZV. The overall certainty of the evidence was moderate, which indicates that the intervention probably works. Most data for the primary outcome (cumulative incidence of herpes zoster) and secondary outcomes (adverse events and dropouts) came from studies that had a low risk of bias and included a large number of participants. The cumulative incidence of herpes zoster at up to three years of follow-up was lower in participants who received the LZV (one dose subcutaneously) than in those who received placebo (risk ratio (RR) 0.49, 95% confidence interval (CI) 0.43 to 0.56; risk difference (RD) 2%; number needed to treat for an additional beneficial outcome (NNTB) 50; moderate-certainty evidence) in the largest study, which included 38,546 participants. There were no differences between the vaccinated and placebo groups for serious adverse events (RR 1.08, 95% CI 0.95 to 1.21) or deaths (RR 1.01, 95% CI 0.92 to 1.11; moderate-certainty evidence). The vaccinated group had a higher cumulative incidence of one or more adverse events (RR 1.71, 95% CI 1.38 to 2.11; RD 23%; number needed to treat for an additional harmful outcome (NNTH) 4.3) and injection site adverse events (RR 3.73, 95% CI 1.93 to 7.21; RD 28%; NNTH 3.6; moderate-certainty evidence) of mild to moderate intensity. These data came from four studies with 6980 participants aged 60 years or older. Two studies (29,311 participants for safety evaluation and 22,022 participants for efficacy evaluation) compared RZV (two doses intramuscularly, two months apart) versus placebo. Participants who received the new vaccine had a lower cumulative incidence of herpes zoster at 3.2 years follow-up (RR 0.08, 95% CI 0.03 to 0.23; RD 3%; NNTB 33; moderate-certainty evidence), probably indicating a favourable profile of the intervention. There were no differences between the vaccinated and placebo groups in cumulative incidence of serious adverse events (RR 0.97, 95% CI 0.91 to 1.03) or deaths (RR 0.94, 95% CI 0.84 to 1.04; moderate-certainty evidence). The vaccinated group had a higher cumulative incidence of adverse events, any systemic symptom (RR 2.23, 95% CI 2.12 to 2.34; RD 33%; NNTH 3.0), and any local symptom (RR 6.89, 95% CI 6.37 to 7.45; RD 67%; NNTH 1.5). Although most participants reported that their symptoms were of mild to moderate intensity, the risk of dropouts (participants not returning for the second dose, two months after the first dose) was higher in the vaccine group than in the placebo group (RR 1.25, 95% CI 1.13 to 1.39; RD 1%; NNTH 100, moderate-certainty evidence). Only one study reported funding from a non-commercial source (a university research foundation). All other included studies received funding from pharmaceutical companies. We did not conduct subgroup and sensitivity analyses AUTHORS' CONCLUSIONS: LZV (single dose) and RZV (two doses) are probably effective in preventing shingles disease for at least three years. To date, there are no data to recommend revaccination after receiving the basic schedule for each type of vaccine. Both vaccines produce systemic and injection site adverse events of mild to moderate intensity. The conclusions did not change in relation to the previous version of the systematic review.
Subject(s)
Chickenpox , Herpes Zoster Vaccine , Herpes Zoster , Humans , Aged , Middle Aged , Herpesvirus 3, Human , Herpes Zoster Vaccine/adverse effects , Chickenpox/chemically induced , Chickenpox/drug therapy , Herpes Zoster/prevention & control , Herpes Zoster/chemically induced , Herpes Zoster/drug therapy , Vaccines, Attenuated/adverse effectsABSTRACT
Post-herpetic neuralgia (PHN) is an entity derived from peripheral nerve damage that occurs during the reactivation of the Varicella Zoster Virus (VZV), which manifests itself through pain with neuropathic characteristics. This can prove to be very difficult to manage in the chronic stages of disease reappearance. There currently exists a multitude of treatment alternatives for PHN, however, prevention through the early initiation of antiviral regimens is vital. There are various pharmacological options available, but it is important to individualize each patient to maximize efficacy and minimize adverse effects. Interventional procedures have become a cornerstone in difficult-to-manage cases, and have shown promising outcomes when used in a multimodal approach by experienced specialists. It is necessary to make an objective diagnosis of PHN and start early treatment. Additionally there is current evidence that vouches for interventional therapies as well as individualization, with a clear establishment of therapeutic objectives according to the needs of each patient.
Subject(s)
Herpes Zoster , Neuralgia, Postherpetic , Humans , Neuralgia, Postherpetic/drug therapy , Herpes Zoster/complications , Herpes Zoster/drug therapy , Herpes Zoster/prevention & control , Herpesvirus 3, Human , Analgesics/therapeutic useABSTRACT
BACKGROUND: Studies have shown that the overall incidence rate of herpeszoster (HZ) in China is 6.64 cases per 1000 people, despite such harms brought by postherpetic neuralgia (PHN), the mechanism of the disease remains unclear in China. Currently, effective biomarkers to predict PHN remain unavailable, which makes it difficult to prevent and successfully treat PHN. OBJECTIVE: The aim of the study was to determine the serum interleukin-6 level in PHN. METHODS: The serum levels of interleukin 6 (IL-6) were measured by multi-antibody sandwich ELISA. The likert scale was used to represent the degree of neuralgia in the patients. Patients with PHN were divided into a mild PHN group and a severe PHN group according to the Likert scale. ROC curve was performed for evaluating the diagnostic efficiency of IL6 for PHN. The correlation between the IL6 level and the Likert scale before and after treatment with gabapentin and mecobalamin was analyzed. RESULTS: IL6 levels in PHN patients resulted higher compared to volunteers. Patients in the severe PHN group had a higher serum IL6 level than in the mild PHN group. The Likert scale score was related to the serum IL6 levels and the frequency of IL6 levels above the cutoff value (4.95â¯pg/mL) in PNH groups before and after treatment (pâ¯<â¯0.05). STUDY LIMITATIONS: Pain is subjective. Some mental states, such as anxiety and depression, greatly influence an individual's perception of pain, and pain tolerance can vary between people. Therefore, pain scores can be affected by different individual factors. CONCLUSIONS: The serum IL6 levels may be used as a biochemical indicator of the severity of PNH.
Subject(s)
Herpes Zoster , Neuralgia, Postherpetic , Humans , Gabapentin , Herpes Zoster/complications , Herpes Zoster/drug therapy , Interleukin-6 , Neuralgia, Postherpetic/drug therapy , Neuralgia, Postherpetic/epidemiology , Neuralgia, Postherpetic/etiology , Retrospective StudiesABSTRACT
El herpes zóster es una enfermedad infecciosa producida por el virus de la varicela zóster, caracterizada por la aparición de vesículas que suelen presentarse en una disposición metamérica. Su incidencia se encuentra en aumento y es un motivo de consulta frecuente en la práctica cotidiana. En este artículo se ofrece información actualizada acerca de su diagnóstico, tratamiento y prevención, así como sobre otros aspectos controvertidos de su manejo.
Herpes zoster is an infectious disease caused by varicella zoster virus, characterized by the development of vesicles, which usually present with a metameric arrangement. Its incidence is increasing and is a frequent reason for consultation in daily practice. This article offers updated information on its diagnosis, treatment and prevention, as well as controversial aspects of the management of this pathology.
Subject(s)
Humans , Male , Female , Herpes Zoster/drug therapy , Herpes Zoster/complications , Herpes Zoster/diagnosis , Herpes Zoster/prevention & controlABSTRACT
Elsberg syndrome (ES) refers to the combination of myelitis and lumbosacral radiculitis associated with infection caused by the virus of the Herpesviridae family. We present a case of a 52-year-old man with a 9 months diagnosis of Crohn's disease, in use of infliximab with good disease control, complaining of 2 months history of progressive urinary retention and loss of sensation of the genital and left lower limb regions associated with varicella zoster virus (VZV) infection and recent HIV diagnosis.
Subject(s)
Chickenpox , Crohn Disease , HIV Infections , Herpes Zoster , Crohn Disease/complications , Crohn Disease/drug therapy , HIV Infections/complications , HIV Infections/drug therapy , Herpes Zoster/complications , Herpes Zoster/drug therapy , Humans , Infliximab/adverse effects , Male , Middle AgedABSTRACT
Herpes zoster classical clinical presentation is the acute onset of multiple vesicles over an erythematous base, disposed over one or two dermatomes with up to 20 vesicles located outside the main dermatome. Disseminated herpes zoster is an atypical and rare form of presentation of herpes zoster, which manifests with lesions beyond the described territory. It occurs mainly in patients with some type of cellular immunosuppression. The diagnosis is made with the medical history and physical examination, however, it should be confirmed with laboratory tests. Treatment must be initiated early to avoid serious complications, such as bacterial infection of the lesions, post-herpetic neuralgia, or even central nervous system involvement. The drug of choice is intravenous acyclovir that must be maintained until the cessation of the appearance of new lesions, and then switch to its oral presentation for another 5-7 days. Disseminated herpes zoster mortality rounds 5-15%. There are varicella-zoster virus vaccines, that have been shown to reduce the incidence of herpes zoster relapses, however its utility to disseminated herpes zoster is uncertain and further studies are required. We present the case of a male patient with a history of rheumatoid arthritis who consults with multiple vesicles distributed throughout his body. (AU)
Subject(s)
Humans , Male , Middle Aged , Herpes Zoster/diagnosis , Acyclovir/administration & dosage , Herpes Zoster/physiopathology , Herpes Zoster/drug therapyABSTRACT
Dermatologists must be familiar with the peculiarities of the micro-organisms that may affect the elderly, in order to optimize the diagnosis and treatment of infections, which may affect their skin, especially because the world population is rapidly aging. It is estimated that there will be 434 million individuals over 80 years of age in 2050. Since the elderly population is rapidly increasing and their infections are usually more severe and different from those observed in younger adults, it leads to a statistical increase of the rates regarding hospitalization and mortality caused by infectious diseases among people over 85 years. Other health issues may be involved in the older population. These include nutritional alterations, as malnutrition or obesity, which can aggravate the infections. Also the usual signs and symptoms of infection are subtle or uncharacteristic in elderly patients, and frequently, they are unable to report their symptoms, which can delay the diagnosis. Among the many infections that may affect the elderly we reviewed the most frequent and those that are different in this age group, as herpes zoster, cytomegalovirus, herpes simplex, bacterial skin infections, erysipelas, celullitis, impetigo, folliculitis, furunculosis and carbunculosis, secondary infections, intertrigo (body folds), fungal infection, and scabies.
Subject(s)
Herpes Zoster/prevention & control , Skin Diseases, Infectious/drug therapy , Skin Diseases, Infectious/microbiology , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Antifungal Agents/therapeutic use , Antiviral Agents/therapeutic use , Cellulitis/diagnosis , Cellulitis/drug therapy , Dermatomycoses/diagnosis , Dermatomycoses/microbiology , Erysipelas/diagnosis , Folliculitis/drug therapy , Folliculitis/microbiology , Herpes Zoster/drug therapy , Humans , Intertrigo/microbiology , Middle Aged , Scabies/diagnosis , Scabies/drug therapy , Skin Diseases, Infectious/diagnosis , Skin Diseases, Infectious/virologyABSTRACT
Se presenta el caso clínico de un niño de 9 años de edad, quien asistió al centro de salud de Santa Lucia, municipio de Itamarandiba, estado brasileño de Minas Gerais, por presentar lesiones inicialmente dolorosas y pruriginosas en el abdomen, que se irradiaban a la espalda unilateralmente. En el examen dermatológico se observaron múltiples vesículas agrupadas en forma de racimo de uvas sobre un fondo eritematoso, localizadas en el lado izquierdo del abdomen y difundidas a la región lumbar, por lo cual se diagnosticó un herpes zóster. Se le indicó el tratamiento oportuno y desaparecieron tanto las lesiones como los síntomas asociados
The case report of a 9 years boy is presented. He attended the health center of Santa Lucía, in Itamarandiba, Brazilian state of Minas Gerais, due to initially painful and pruriginous lesions in the abdomen that irradiated unilaterally to the back. In the dermatologic examination multiple vesicles grouped in a bunch of grapes form on an erythematosus base were observed, located in the left side of the abdomen and diffused to the lumbar region, reason why an herpes zoster was diagnosed. The appropriate treatment was indicated and either the lesions or the associated symptoms disappeared
Subject(s)
Humans , Male , Child , Herpes Zoster/diagnosis , Herpes Zoster/drug therapy , Skin Manifestations , Brazil , ExanthemaABSTRACT
Se describe el caso de un paciente de 16 años, inmunocompetente, con herpes zoster localizado en la región glútea izquierda, que evolucionó satisfactoriamente. El paciente tiene antecedente de no estar vacunado con la vacuna antivaricela ni haberse contagiado de la varicela, su madre padeció esta enfermedad a las 28 semanas de su embarazo. El herpes zoster aparece cada vez más en la adolescencia e infancia. La localización glútea es una localización poco frecuente(AU)
The case is described of an immunocompetent 16-year-old female patient with herpes zoster located in the left gluteal region, which evolved satisfactorily. The patient has a history of not being vaccinated with the vaccine anicaricela nor infected with chickenpox, her mother suffered from this disease at 28 weeks of pregnancy. Herpes zoster appears more and more in adolescence and childhood. The gluteal location is a rare location(AU)
Subject(s)
Humans , Male , Adolescent , Herpes Zoster/diagnosis , Herpes Zoster/drug therapy , ImmunocompetenceABSTRACT
Herpes zoster (HZ) is caused by reactivation of the varicella zoster virus. Its main risk factor is increasing age and comorbidities. There are limited data on the characteristics of HZ in South America, especially in the elderly. We analyzed epidemiological and clinical characteristics of 340 patients over 60 years assisted for HZ, between June 2013 and May 2014. The average age was 74 years (60-100), 62% (210) had thoracic location; 75% (255) of the initial consultations were held in guards; 68% (143) had pain and vesicles, and 4% (14) only pain at baseline. Pain persisted after finishing the episode in 41% (139). The diagnosis was made between 1 and 3 days from the beginning of the episode in 53% (180 patients). Average number of visits per episode was 3.6 (1-24). Antiviral treatment was supplied to 91% (309); however it was inadequate in dose or time in 49.1% (167 cases). Pain treatment was indicated in 66% (224). Most frequently used drugs (alone or in combination) were non-steroidal painkillers (43%, 146), pregabalin (30%, 102), opiates (24%, 82), and steroids (12%, 41); 9% (31) presented comorbidities; 27% (126) experienced pain after the ending of the episode, with an average duration of 138.7 days. In general, diagnosis was done late, making it difficult to use antivirals correctly. The presence of pain was more frequent than reported in other publications, however there are few data in this age group.
Subject(s)
Herpes Zoster , Age Distribution , Aged , Aged, 80 and over , Antiviral Agents/therapeutic use , Argentina , Female , Herpes Zoster/complications , Herpes Zoster/drug therapy , Herpes Zoster/pathology , Hospitals, Community , Humans , Incidence , Male , Middle Aged , Neuralgia/etiology , Retrospective Studies , Risk FactorsABSTRACT
El herpes zoster (HZ) se produce por reactivación del virus varicela zoster. Sus principales factores de riesgo son edad avanzada y presencia de comorbilidades (diabetes, inmunodepresión). Existen escasos datos de HZ en Sudamérica, y especialmente en adultos mayores. Analizamos retrospectivamente las características epidemiológicas y clínicas de 340 pacientes mayores de 60 años atendidos por HZ, entre junio 2013 y mayo 2014. La edad promedio de consulta fue de 74 años (60-100), localización torácica 210 (62%); el 75% (255) de las consultas iniciales se realizaron en guardias. El 68%, 143, presentaron dolor y vesículas, y 4% (14) solo dolor al inicio; el dolor persistió luego de finalizar el episodio en el 41% (139) de los pacientes. El diagnóstico se realizó entre 1 y 3 días de iniciado el cuadro en el 53% (180). El promedio de consultas por episodio fue de 3.6 (1-24). Tratamiento antiviral se indicó en 91% (309) de los pacientes [en 49% (167) fue inadecuado en tiempo o dosis], y tratamiento para el dolor en el 66% (224) de los casos: drogas más usadas (solas o en combinación) AINES (43%, 146), pregabalina (30%, 102), opiáceos (24%, 82), y corticoides (12%, 41). Solo el 9% (31) presentó comorbilidades y el 27% (126) dolor post episodio (duración promedio: 138.7 días). El diagnóstico fue tardío, dificultando el uso correcto de antivirales. El dolor post episodio fue más frecuente que en la literatura consultada; sin embargo, son pocos los datos en este grupo etario.
Herpes zoster (HZ) is caused by reactivation of the varicella zoster virus. Its main risk factor is increasing age and comorbidities. There are limited data on the characteristics of HZ in South America, especially in the elderly. We analyzed epidemiological and clinical characteristics of 340 patients over 60 years assisted for HZ, between June 2013 and May 2014. The average age was 74 years (60-100), 62% (210) had thoracic location; 75% (255) of the initial consultations were held in guards; 68% (143) had pain and vesicles, and 4% (14) only pain at baseline. Pain persisted after finishing the episode in 41% (139). The diagnosis was made between 1 and 3 days from the beginning of the episode in 53% (180 patients). Average number of visits per episode was 3.6 (1-24). Antiviral treatment was supplied to 91% (309); however it was inadequate in dose or time in 49.1% (167 cases). Pain treatment was indicated in 66% (224). Most frequently used drugs (alone or in combination) were non-steroidal painkillers (43%, 146), pregabalin (30%, 102), opiates (24%, 82), and steroids (12%, 41); 9% (31) presented comorbidities; 27% (126) experienced pain after the ending of the episode, with an average duration of 138.7 days. In general, diagnosis was done late, making it difficult to use antivirals correctly. The presence of pain was more frequent than reported in other publications, however there are few data in this age group.
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Aged, 80 and over , Herpes Zoster/complications , Herpes Zoster/pathology , Herpes Zoster/drug therapy , Antiviral Agents/therapeutic use , Argentina , Incidence , Retrospective Studies , Risk Factors , Age Distribution , Hospitals, Community , Neuralgia/etiologyABSTRACT
Zóster é uma doença viral pelo qual o mecanismo de reativação, ainda é pouco compreendido. Entretanto, parece estar relacionado com algum tipo de deficiência na imunidade, além do estresse também ser apontado como fator desencadeante. O diagnóstico, na maioria das vezes, é eminentemente clínico, usualmente determinado por lesões vesículobolhosas que envolvem a pele ao longo do trajeto do nervo branquial. O objetivo desse trabalho é relatar um caso clínico de uma paciente, 21 anos de idade, diagnosticada com zóster e comprometimento do nervo trigêmeo, nos ramos oftálmico, maxilar e mandibular. Verificouse aumento de volume em região de terços médio e inferior da face esquerda, edema palpebral, linfadenopatia em região submandibular, lesões cutâneas vesículo-bolhosas em região periorbital, massetérica, geniana e submandibular. As lesões não ultrapassavam a linha média da face. Após o tratamento a paciente não apresentou sequelas. Salientase a necessidade do conhecimento dessas lesões por parte do cirurgião dentista, a fim de estabelecer diagnóstico e tratamento imediato, para minimizar sintomatologia e acompanhamento da neuralgia pós-zóster... (AU)
Zoster is a viral disease in which the reactivation mechanism is poorly understood. However, it seems to be related to an immunity disability, in addition to stress, which is also be appointed as a triggering factor. The diagnosis, in most cases, is eminently clinical, usually determined by vesicle-bullous lesions involving the skin over the brachial nerve pathway. The aim of this study is to report a case of a 21-year-old patient, diagnosed with zoster, with commitment of the trigeminal nerve comprehending the ophthalmic, maxillary and mandibular branches. There was tissue growth in medium-third region and the lower left cheek, eyelid edema, lymphadenopathy in the submandibular region, vesicle-bullous skin lesions in the periorbital, masseteric, genian and submandibular regions. The injury did not exceed the midline of the face. After treatment the patient had no sequelae. It is emphasized the need of understanding these lesions by the dental surgeon, in order to establish diagnosis and the due immediate treatment in order to reduce the symptoms and the follow up of post-zoster neuralgia... (AU)
Subject(s)
Humans , Female , Young Adult , Trigeminal Nerve Diseases/virology , Herpes Zoster/diagnosis , Antiviral Agents/therapeutic use , Acyclovir/therapeutic use , Herpes Zoster/drug therapyABSTRACT
OBJECTIVE: The aim of this multicenter study in a large childhood-onset systemic lupus erythematosus (cSLE) population was to assess the herpes zoster infection (HZI) prevalence, demographic data, clinical manifestations, laboratory findings, treatment, and outcome. METHODS: A retrospective multicenter cohort study (Brazilian cSLE group) was performed in ten Pediatric Rheumatology services in São Paulo State, Brazil, and included 852 cSLE patients. HZI was defined according to the presence of acute vesicular-bullous lesions on erythematous/edematous base, in a dermatomal distribution. Post-herpetic neuralgia was defined as persistent pain after one month of resolution of lesions in the same dermatome. Patients were divided in two groups for the assessment of current lupus manifestations, laboratory findings, and treatment: patients with HZI (evaluated at the first HZI) and patients without HZI (evaluated at the last visit). RESULTS: The frequency of HZI in cSLE patients was 120/852 (14%). Hospitalization occurred in 73 (61%) and overlap bacterial infection in 16 (13%). Intravenous or oral aciclovir was administered in 113/120 (94%) cSLE patients at HZI diagnosis. None of them had ophthalmic complication or death. Post-herpetic neuralgia occurred in 6/120 (5%). After Holm-Bonferroni correction for multiple comparisons, disease duration (1.58 vs 4.41 years, p < 0.0001) was significantly lower in HZI cSLE patients compared to those without HZI. Nephritis (37% vs 18%, p < 0.0001), lymphopenia (32% vs 17%, p < 0.0001) prednisone (97% vs 77%, p < 0.0001), cyclophosphamide (20% vs 5%, p < 0.0001) and SLE Disease Activity Index 2000 (6.0 (0-35) vs 2 (0-45), p < 0.0001) were significantly higher in the former group. The logistic regression model showed that four independent variables were associated with HZI: disease duration < 1 year (OR 2.893 (CI 1.821-4.597), p < 0.0001), lymphopenia <1500/mm(3) (OR 1.931 (CI 1.183-3.153), p = 0.009), prednisone (OR 6.723 (CI 2.072-21.815), p = 0.002), and cyclophosphamide use (OR 4.060 (CI 2.174-7.583), p < 0.0001). CONCLUSION: HZI is an early viral infection in cSLE with a typical dermatomal distribution. Lymphopenia and immunosuppressive treatment seem to be major factors underlying this complication in spite of a benign course.
Subject(s)
Cyclophosphamide/adverse effects , Herpes Zoster/epidemiology , Immunosuppressive Agents/adverse effects , Lupus Erythematosus, Systemic/complications , Prednisone/adverse effects , Acyclovir/administration & dosage , Adolescent , Adult , Age of Onset , Antiviral Agents/administration & dosage , Brazil/epidemiology , Child , Child, Preschool , Female , Herpes Zoster/drug therapy , Hospitalization/statistics & numerical data , Humans , Infant , Logistic Models , Lupus Erythematosus, Systemic/drug therapy , Lymphopenia/epidemiology , Male , Nephritis/epidemiology , Retrospective Studies , Severity of Illness Index , Young AdultABSTRACT
The varicella zoster virus is the causative agent of herpes zoster and varicella. In herpes zoster, the virus dormant within dorsal root ganglia is reactivated, resulting in painful vesicular lesions overlying an erythematous base.
Subject(s)
Herpes Zoster/pathology , Acyclovir/therapeutic use , Antiviral Agents/therapeutic use , Female , Herpes Zoster/drug therapy , Humans , Middle AgedABSTRACT
Summary The varicella zoster virus is the causative agent of herpes zoster and varicella. In herpes zoster, the virus dormant within dorsal root ganglia is reactivated, resulting in painful vesicular lesions overlying an erythematous base.
Resumo Caso típico: herpes-zóster. O vírus varicela-zóster é o agente causador das doenças herpes-zóster e varicela. No caso do herpes-zóster, ocorre reativação do vírus que está alojado nos gânglios da raiz dorsal de gânglios simpáticos, resultando em lesões vesiculares dolorosas, agrupadas em uma base eritematosa.
Subject(s)
Humans , Female , Herpes Zoster/pathology , Antiviral Agents/therapeutic use , Acyclovir/therapeutic use , Herpes Zoster/drug therapy , Middle AgedABSTRACT
Varicella-zoster virus (VZV) is herpes virus that after its reactivation from nerve ganglia to cause herpes zoster may lead to a variety of neurologic complications, including encephalitis, meningitis, retinal necrosis or myelitis. In addition, VZV can spread to arteries in the central nervous system and cause hemorrhagic or ischemic complications due to an inflammatory vasculopathy. In fact, there is a growing epidemiological and clinical recognition that there is an association between VZV reactivation and subsequent strokes. Herein, we present a case of an immune compromised individual with reactivation of VZV causing dermatomal herpes zoster followed by multifocal vasculopathy. We also review the literature to highlight key aspects of VZV-associated vasculopathy.
Subject(s)
Brain Ischemia/virology , Herpes Zoster/virology , Stroke/virology , Acyclovir/administration & dosage , Acyclovir/therapeutic use , Antibodies, Viral/blood , Antiviral Agents/administration & dosage , Antiviral Agents/therapeutic use , Brain Ischemia/drug therapy , Brain Ischemia/pathology , Herpes Zoster/drug therapy , Herpes Zoster/pathology , Herpesvirus 3, Human/isolation & purification , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Stroke/pathologyABSTRACT
Herpes zoster-associated urinary retention is an uncommon event related to virus infection of the S2-S4 dermatome. The possible major reasons are ipsilateral hemicystitis, neuritis-induced or myelitis-associated virus infection. We report a case of a 65-year-old immunocompetent female patient who presented an acute urinary retention after four days under treatment with valacyclovir for gluteal herpes zoster. The patient had to use a vesical catheter, was treated with antibiotics and corticosteroids and fully recovered after eight weeks.
Subject(s)
Aged , Female , Humans , Exanthema/virology , Herpes Zoster/complications , Immunocompetence , Urinary Retention/virology , Acyclovir/analogs & derivatives , Acyclovir/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Antiviral Agents/therapeutic use , Exanthema/drug therapy , Herpes Zoster/drug therapy , Herpes Zoster/immunology , Immunocompetence/immunology , Treatment Outcome , Valine/analogs & derivatives , Valine/therapeutic useABSTRACT
Herpes zoster-associated urinary retention is an uncommon event related to virus infection of the S2-S4 dermatome. The possible major reasons are ipsilateral hemicystitis, neuritis-induced or myelitis-associated virus infection. We report a case of a 65-year-old immunocompetent female patient who presented an acute urinary retention after four days under treatment with valacyclovir for gluteal herpes zoster. The patient had to use a vesical catheter, was treated with antibiotics and corticosteroids and fully recovered after eight weeks.